Table 2.

Clinical characteristics and therapy

	Child at Disease Onset (n=304)	Adolescent at Disease Onset (n=49)	Adult at Disease Onset (n=201)	P-value
Days between onset and biopsy	238 (85,663)	23 (11,62)	36 (16,93)	<0.001
UPCR at Biopsy *	3.0 (0.4-8.9)	5.6 (1.0-8.3)	6.9 (3.6-10.0)	<0.001
UPCR at Disease Onset *	7.5 (2.3-12.2)	4.6 (1.0-10.7)	6.5 (2.8-10.0)	0.2
eGFR (mL/min/1.73m^2) at Biopsy**	139 (110-173)	95 (78-114)	88 (63-108)	<0.001
eGFR (mL/min/1.73m^2) at Disease onset**	127 (101-165)	100 (67-114)	89 (64-109)	<0.001
Serum albumin (g/dL) at Biopsy***	2.6 (1.8-3.3)	1.9 (1.6-2.4)	2.2 (1.7-2.8)	0.002
Serum albumin (g/dL) at Disease Onset***	1.8 (1.3-2.4)	1.9 (1.7-2.3)	2.2 (1.7-2.8)	0.002
Hypertension, n(%)	99 (33%)	7 (14%)	94 (47%)	0.001
Steroid Response Classification at Enrollment				<0.001
Infrequently Relapsing	24 (8%)	6 (12%)	30 (15%)
FRNS/SDNS	173 (57%)	9 (18%)	56 (29%)
Steroid Resistant	50 (16%)	11 (22%)	22 (11%)
Multi-drug resistant	6 (2%)	0 (0%)	8 (4%)
Untreated	14 (5%)	6 (12%)	15 (8%)
Unknown	38 (12%)	18 (36%)	65 (33%)
Immunosuppression prior to biopsy
Any Immunosuppression	245 (81%)	16 (33%)	51 (26%)	<0.001
Corticosteroids	231 (76%)	16 (33%)	45 (23%)	<0.001
CNIa	44 (15%)	1 (2%)	4 (2%)	<0.001
Rituximaba	8 (3%)	0 (0%)	5 (5%)	0.5
Mycophenolatea	20 (7%)	1 (2%)	2 (1%)	0.007
RAAS Blockade prior to biopsy	23 (8%)	4 (8%)	39 (20%)	<0.001

^*missing at biopsy: 115 (38%) pediatric, 13 (26%) adolescent, 69 (36%) adult, missing at disease onset: 193 (66%) pediatric 28 (56%) adolescent and 87 (46%) adult-onset participants

^**missing at biopsy: 74 (24%) pediatric, 6 (12%) adolescent, 50 (26%) adult, missing at disease onset: 186 (61%) pediatric, 23 (46%) Adolescent-, 89 (47%) adult-onset participants

^***missing at biopsy: 90 (30%) pediatric, 8 (16%) adolescent, 3 (31%) adult, missing at disease onset: 189 (62%) pediatric 24 (48%), 87 (46%) adult-onset participants

FRNS/SDNS – frequently relapsing nephrotic syndrome/steroid dependent nephrotic syndrome

^aFisher’s exact test.